Supernus Q1 Revenue Surges 39% to $207.7M, Reaffirms Full-Year Guidance
SUPN sits 77% above its 52-week low of $29.16.
Summary
Supernus Pharmaceuticals reported robust first-quarter 2026 results, with total revenues climbing 39% year-over-year to $207.7 million. The company posted adjusted operating earnings of $28.7 million, alongside a net loss of $2.3 million, or $(0.04) per share. This strong revenue performance, driven by a 56% increase in combined growth product revenues, marks a significant improvement compared to the substantial net and operating losses reported for the full year 2025. The reiteration of full-year 2026 guidance, coupled with the strong Q1 growth, suggests positive operational momentum and could alleviate prior concerns regarding profitability. Investors will be watching for continued growth in key products like Qelbree and GOCOVRI, as well as the anticipated FDA submission for a second ONAPGO supplier in Q3 2026.
At the time of this announcement, SUPN was trading at $51.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $29.16 to $59.68. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.